News Sentiment

ICCM sentiment intelligence

Icecure Medical news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 65 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 5.40 Week of 19 Jun 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 65

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+125.9% over one week, -23.4% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

This Undervalued Medical-Devices Stock Is Poised for a Rebound

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction 125.9% Price confirming higher
Trend fit Trend inactive -23.4% over four weeks
Fair value -79.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 42
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 65
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 15
Stock Titan 12
PR Newswire 7
GuruFocus 3
TechStock² 2
Benzinga 2
TradingView 2
StockStory 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 24
Macro sensitivity 2
Regulatory and legal 2
Deals and strategy 1
Guidance 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 65
www.marketscreener.com Direct company coverage

IceCure Medical Ltd. Reports Nearly 90% Recurrence-Free Rate For Cryoablation Of Kidney Cancer And Showcases ProSense At ECIO 2026

IceCure Medical Ltd. announced impressive results for its ProSense cryoablation system at ECIO 2026, highlighting an 89.4% recurrence-free rate for kidney cancer patients with tumors measuring 3 cm or less. The company also showcased positive data for breast cancer and fibroadeno

Tone
Positive 70/100
Event
Earnings
Published
19 May 2026 20:39
Source
www.marketscreener.com
PR Newswire Direct company coverage

IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked

IceCure Medical announced significant clinical data at ECIO 2026, highlighting the efficacy of its ProSense® cryoablation technology. The ICESECRET trial showed an 89.4% recurrence-free rate for kidney cancer patients with small tumors, while independent breast cancer studies rep

Tone
Positive 92/100
Event
Market update
Published
19 May 2026 19:39
Source
PR Newswire
TipRanks Direct company coverage

IceCure Showcases Strong ProSense® Cryoablation Data and Surge in Clinical Interest at ECIO 2026

IceCure Medical presented strong long-term data for its ProSense® cryoablation technology at ECIO 2026, including high recurrence-free rates for kidney cancer and safe, effective outcomes for breast cancer. The conference also saw an enthusiastic response to breast cryoablation t

Tone
Neutral 50/100
Event
Macro sensitivity
Published
19 May 2026 13:40
Source
TipRanks
Stock Titan Direct company coverage

IceCure Medical (ICCM) highlights kidney and breast cryoablation data at ECIO 2026

IceCure Medical announced new clinical data from its ProSense® cryoablation system for kidney and breast tumors, presented at ECIO 2026. The data showed an 89.4% recurrence-free rate in kidney cancer patients with tumors ≤3 cm and 83.9% overall at a 4-year follow-up. Independent

Tone
Positive 71/100
Event
Market update
Published
19 May 2026 12:40
Source
Stock Titan
Stock Titan Direct company coverage

IceCure Medical (ICCM) CFO reports 400,000 RSUs equity grant

IceCure Medical Ltd.'s CFO, Peleg Meir, has been granted 400,000 restricted share units (RSUs) as part of his equity compensation. The RSUs have a multi-year vesting schedule, with 25% vesting on May 17, 2027, and the remaining 75% vesting in equal quarterly installments of 6.25%

Tone
Neutral 50/100
Event
Market update
Published
18 May 2026 11:38
Source
Stock Titan